Literature DB >> 30019928

miRNA in a multiomic context for diagnosis, treatment monitoring and personalized management of metastatic breast cancer.

Pavol Zubor1,2, Peter Kubatka2,3, Zuzana Dankova2, Alexandra Gondova1, Karol Kajo4,5, Jozef Hatok6, Marek Samec1,2, Marianna Jagelkova1,2, Stefan Krivus1, Veronika Holubekova2, Jan Bujnak7,8, Zuzana Laucekova1, Katarina Zelinova1,2, Igor Stastny1,2, Marcela Nachajova1, Jan Danko1, Olga Golubnitschaja9,10,11.   

Abstract

Metastatic breast cancer is characterized by aggressive spreading to distant organs. Despite huge multilevel research, there are still several important challenges that have to be clarified in the management of this disease. Therefore, recent investigations have implemented a modern, multiomic approach with the aim of identifying specific biomarkers for not only early detection but also to predict treatment responses and metastatic spread. Specific attention is paid to short miRNAs, which regulate gene expression at the post-transcriptional level. Aberrant miRNA expression could initiate cancer development, cell proliferation, invasion, migration, metastatic spread or drug resistance. An miRNA signature is, therefore, believed to be a promising biomarker and prediction tool that could be utilized in all phases of carcinogenesis. This article offers comprehensive information about miRNA profiles useful for diagnostic and treatment purposes that may sufficiently advance breast cancer management and improve individual outcomes in the near future.

Entities:  

Keywords:  individual outcome; metastasis; miRNA; personalized medicine; prediction; prevention;  breast cancer

Mesh:

Substances:

Year:  2018        PMID: 30019928     DOI: 10.2217/fon-2018-0061

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  10 in total

1.  CRISPR/Cas9 mediated knocking out of OPN gene enhances radiosensitivity in MDA-MB-231 breast cancer cell line.

Authors:  Rahil Ghanbarnasab Behbahani; Amir Danyaei; Ali Teimoori; Mohammad Javad Tahmasbi; Niloofar Neisi
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-30       Impact factor: 4.322

Review 2.  MicroRNAs as therapeutic targets in breast cancer metastasis.

Authors:  Fahima Danesh Pouya; Yousef Rasmi; Maria Gazouli; Eleni Zografos; Mohadeseh Nemati
Journal:  Drug Deliv Transl Res       Date:  2021-05-13       Impact factor: 4.617

Review 3.  Why the Gold Standard Approach by Mammography Demands Extension by Multiomics? Application of Liquid Biopsy miRNA Profiles to Breast Cancer Disease Management.

Authors:  Pavol Zubor; Peter Kubatka; Karol Kajo; Zuzana Dankova; Hubert Polacek; Tibor Bielik; Erik Kudela; Marek Samec; Alena Liskova; Dominika Vlcakova; Tatiana Kulkovska; Igor Stastny; Veronika Holubekova; Jan Bujnak; Zuzana Laucekova; Dietrich Büsselberg; Mariusz Adamek; Walther Kuhn; Jan Danko; Olga Golubnitschaja
Journal:  Int J Mol Sci       Date:  2019-06-13       Impact factor: 5.923

4.  Platelet Volume Is Reduced In Metastasing Breast Cancer: Blood Profiles Reveal Significant Shifts.

Authors:  Ming-Ming Li; Chen-Xi Yue; Shuang Fu; Xin Zhang; Chang-Jiu Zhao; Rui-Tao Wang
Journal:  Cancer Manag Res       Date:  2019-10-24       Impact factor: 3.989

5.  Mi-RNA-888-5p Is Involved in S-Adenosylmethionine Antitumor Effects in Laryngeal Squamous Cancer Cells.

Authors:  Martina Pagano; Laura Mosca; Francesca Vitiello; Concetta Paola Ilisso; Alessandra Coppola; Luigi Borzacchiello; Luigi Mele; Francesca Pia Caruso; Michele Ceccarelli; Michele Caraglia; Giovanna Cacciapuoti; Marina Porcelli
Journal:  Cancers (Basel)       Date:  2020-12-07       Impact factor: 6.639

Review 6.  Blood Circulating Non-Coding RNAs for the Clinical Management of Triple-Negative Breast Cancer.

Authors:  Tomasz Powrózek; Michael Ochieng Otieno
Journal:  Cancers (Basel)       Date:  2022-02-04       Impact factor: 6.639

7.  Mapping Research on miRNAs in Cancer: A Global Data Analysis and Bibliometric Profiling Analysis.

Authors:  Peter Shaw; Kartik Lokhotiya; Chellan Kumarasamy; Krishnan Sunil; Deepa Suresh; Sameep Shetty; Gothandam Kodiveri Muthukaliannan; Siddhartha Baxi; Ravishankar Ram Mani; Palanisamy Sivanandy; Harish C Chandramoorthy; Madan Mohan Gupta; Suja Samiappan; Rama Jayaraj
Journal:  Pathophysiology       Date:  2022-02-25

8.  MicroRNA-221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signaling.

Authors:  Yingchun Yin; Xinmei Wang; Tangyue Li; Qi Ren; Liang Li; Xiaoyu Sun; Baohua Zhang; Xinyun Wang; Hongmei Han; Yangyang He; Zhen Cao; Xiaojie Sun; Ziqiang Zhou
Journal:  Cancer Med       Date:  2020-01-03       Impact factor: 4.452

Review 9.  Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer.

Authors:  Tala M Abu Samaan; Marek Samec; Alena Liskova; Peter Kubatka; Dietrich Büsselberg
Journal:  Biomolecules       Date:  2019-11-27

Review 10.  miRNA Expression Profiles in Luminal A Breast Cancer-Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment.

Authors:  Erik Kudela; Marek Samec; Lenka Koklesova; Alena Liskova; Peter Kubatka; Erik Kozubik; Tomas Rokos; Terezia Pribulova; Eva Gabonova; Marek Smolar; Kamil Biringer
Journal:  Int J Mol Sci       Date:  2020-10-17       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.